drugset
drugset / Trial / NCT01447576

Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder

NCT01447576 ↗

Phase 2 Completed 1036 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the long-term safety, tolerability and efficacy of oral OPC-34712 as adjunctive therapy in the treatment of adult patients with Major Depressive Disorder (MDD).

Timeline

Start
2009-09
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Brexpiprazole Small molecule 0.25 mg Oral
Subject Brexpiprazole Small molecule 3 mg Oral

Indications

major depressive disorder